Ryan Brown joined Sarepta in February 2018 as vice president, global chief compliance officer and regulatory counsel. He was named general counsel in February 2021, and prior to that, he served as interim general counsel and became a member of the Executive Committee in December 2020. As chief general counsel, Ryan is responsible for the Company’s global legal and compliance functions.
Before entering the biotechnology and pharmaceuticals industry, Ryan specialized in corporate criminal investigations at the international law firm of Jones Day. In 2008, a fortuitous call from a recruiter with an opportunity matching his specific background – at a local company called Allergan, Inc. – changed everything, and he fell into the industry and loved it.
At Allergan, Ryan served as vice president, chief compliance officer where he was responsible for the strategic vision and management of its global corporate compliance program and held other senior positions including general counsel for subsidiary SkinMedica and chief of staff to the office of the president. After Allergan, Ryan served as vice president, chief compliance officer at Acadia Pharmaceuticals where he was responsible for creating, implementing, and managing its corporate compliance program.
Nearly a decade after that fateful call, Ryan was drawn to Sarepta by the company’s mission, powerful science, and strong leadership team.
During his time at Sarepta, Ryan has been impressed by “the passion and willingness of employees to speak up and make sure that there's no gap in the daily decision-making. There’s a high degree of engagement and courage that employees have to communicate their ideas. There's not a correlation between positions and titles and the quality of ideas and contributions.”
On the subject what makes a good lawyer, Ryan had this to say, “Humility, good judgment and an appreciation for the broad swath of human conditions are far more important to the sound practice of law than any technical knowledge of a code or rule.”
Ryan received his Bachelor of Arts degree in Political Science from Loyola Marymount University and his Juris Doctor degree from Harvard Law School.
What is Ryan Edward Brown's net worth?
The estimated net worth of Ryan Edward Brown is at least $2.09 million as of June 25th, 2024. Mr. Brown owns 17,129 shares of Sarepta Therapeutics stock worth more than $2,088,025 as of December 26th. This net worth approximation does not reflect any other investments that Mr. Brown may own. Additionally, Mr. Brown receives an annual salary of $823,360.00 as EVP at Sarepta Therapeutics. Learn More about Ryan Edward Brown's net worth.
How old is Ryan Edward Brown?
Mr. Brown is currently 46 years old. There are 3 older executives and no younger executives at Sarepta Therapeutics. The oldest executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who is 61 years old. Learn More on Ryan Edward Brown's age.
What is Ryan Edward Brown's salary?
As the EVP of Sarepta Therapeutics, Inc., Mr. Brown earns $823,360.00 per year. There are 3 executives that earn more than Mr. Brown. The highest earning executive at Sarepta Therapeutics is Mr. Douglas S. Ingram Esq., President, CEO & Director, who commands a salary of $1,620,000.00 per year. Learn More on Ryan Edward Brown's salary.
How do I contact Ryan Edward Brown?
Has Ryan Edward Brown been buying or selling shares of Sarepta Therapeutics?
Ryan Edward Brown has not been actively trading shares of Sarepta Therapeutics during the last ninety days. Most recently, Ryan Edward Brown sold 38,957 shares of the business's stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $161.61, for a transaction totalling $6,295,840.77. Following the completion of the sale, the executive vice president now directly owns 17,129 shares of the company's stock, valued at $2,768,217.69. Learn More on Ryan Edward Brown's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
